Abstract:Background Patients with hypertension and diabetes mellitus are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. Glucagon‐like peptide‐1 receptor agonists have neuroprotective effects in experimental studies. We aimed to assess the effect of liraglutide, a glucagon‐like peptide‐1 receptor agonist, on cognitive function and whether its effect was associated with metabolic changes in patients with type 2 diabetes mellitus. Methods and Results Fifty patients with type 2 diabetes mellitus were recruited in this prospective study. All patients underwent cognitive assessment and brain activation monitoring by functional near‐infrared spectroscopy. At 12 weeks, patients in the glucagon‐like peptide‐1 group acquired better scores in all cognitive tests and showed remarkable improvement in memory and attention ( P =0.040) test compared with the control group after multivariable adjustment. Compared with the control group, liraglutide significantly increased activation of the dorsolateral prefrontal cortex and orbitofrontal cortex brain regions ( P =0.0038). After liraglutide treatment, cognitive scores were significantly correlated with changes in these activating brain regions ( P <0.05), but no correlation was observed between the changes in cognitive function and changes of body mass index, blood pressure, and glycemic levels. Conclusions We concluded that liraglutide improves cognitive decline in patients with type 2 diabetes mellitus. This beneficial effect is independent of its hypoglycemic effect and weight loss. The optimal intervention should be targeted to cognitive decline in the early stages of dementia. Registration URL: https://www.ClinicalTrials.gov ; Unique identifier: NCT03707171. Nonstandard Abbreviations and Acronyms DLPFC dorsolateral prefrontal cortex fNIRS functional near‐infrared spectroscopy GLP‐1 RAs glucagon‐like peptide‐1 receptor agonists MMSE Mini‐Mental State Examination OFC orbitofrontal cortex VFT verbal fluency task Clinical Perspective What Is New? We examined liraglutide‐related cognitive improvement and demonstrated its neuroprotective effect in patients with diabetes mellitus without severe obesity. Liraglutide significantly improved brain activities and alleviated cognitive decline in patients with diabetes mellitus, compared with other oral antidiabetic drugs. The neuroprotective effect of liraglutide was not related to metabolic improvement, including blood pressure, blood lipids, glycemia. and body weight in patients with diabetes mellitus. What Are the Clinical Implications? This study provided evidence of glucagon‐like peptide‐1 effects on the central nervous system in patients with diabetes mellitus. Early liraglutide treatment might have a beneficial effect on cognitive decline in patients with diabetes mellitus. Glucagon‐like peptide‐1 receptor agonists might be promising drugs to improve cognitive dysfunction, however, these findings need to be confirmed in randomized controlled trials. Alzheimer disease (AD) is highly prevalent worldwide. 1 Type 2 diabetes mellitus (T2DM), hypertension, and obesity have been recognized as major risk factors for cognitive decline and AD. 2 Importantly, patients with hypertension with diabetes mellitus usually display features of cognitive decline, such as defects in verbal memory and fluency, attention, and executive function. 3 The underlying mechanism linking metabolic disorders and cognitive decline remains elusive although numerous studies have suggested that vascular and/or metabolic dysfunction might be involved. <sup -Abstract Truncated-

Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model

Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats

Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes.

The Neuroprotection of Liraglutide on Diabetic Cognitive Deficits is Associated with Improved Hippocampal Synapses and Inhibited Neuronal Apoptosis.

Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux

Subcutaneous Administration of Liraglutide Ameliorates Learning and Memory Impairment by Modulating Tau Hyperphosphorylation Via the Glycogen Synthase Kinase-3Β Pathway in an Amyloid Β Protein Induced Alzheimer Disease Mouse Model

Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease

Trelagliptin relieved cognitive impairment of diabetes mellitus rats: Involvement of PI3K/Akt/GSK-3β and inflammation pathway

Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients with Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.

Subcutaneous Liraglutide Ameliorates Methylglyoxal-Induced Alzheimer-like Tau Pathology and Cognitive Impairment by Modulating Tau Hyperphosphorylation and Glycogen Synthase Kinase-3Β.

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.

Liraglutide Alleviates Cognitive Deficit in db/db Mice: Involvement in Oxidative Stress, Iron Overload, and Ferroptosis

A Novel Thiazolidinediones ATZD2 Rescues Memory Deficits in a Rat Model of Type 2 Diabetes Through Antioxidant and Anti-Inflammation

The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways

P1‐181: DULAGLUTIDE IMPROVES LEARNING AND MEMORY IMPAIRMENT, HYPERPHOSPHORYLATED TAU AND NEUROFILAMENTS IN THE APP/PS1/TAU TRIPLE TRANSGENIC MICE

Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats

Liraglutide protects from renal damage via Akt-mTOR pathway in rats with diabetic kidney disease

Topical Ocular Administration of the GLP-1 Receptor Agonist Liraglutide Arrests Hyperphosphorylated Tau-Triggered Diabetic Retinal Neurodegeneration Via Activation of GLP-1R/Akt/GSK3β Signaling.

Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model

Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin‐induced diabetic rats